Quebec Government Invests $1.38M in Neurenati Therapeutics for NEU-001 Clinical Trials

The Quebec Government's $1.38 million investment in Neurenati Therapeutics for NEU-001 clinical trials brings the total funding to $2.9 million. Neurenati aims to file a clinical trial application in Canada and the United States by the end of 2025, while expressing ongoing interest in exploring new technologies for rare diseases, especially in pediatrics.